Role of anti-citrullinated protein antibodies in diagnosis and prognosis of rheumatoid arthritis

Puszczewicz, Mariusz; Iwaszkiewicz, Cezary

doi:10.5114/aoms.2011.22067

Cited by 47 publications

(35 citation statements)

References 49 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though anti-CCP was positive in the current case, the patient did not show any specific symptoms of RA. 4 In addition, it should be noted that the RA had not been progressed for the past ten years and the patient was asymptomatic in between the episodic occurrence of the disease. Ultrasound examination of the elbows, wrists and knees was normal.…”

Section: Discussionmentioning

confidence: 99%

Chronic tophaceous gout with anti-CCP positivity: A rare presentation

Haridas¹,

Haridas²,

Gadagi³

2016

IJRCI

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Chronic tophaceous gout with anti-CCP positivity: A rare presentation

Haridas¹,

Haridas²,

Gadagi³

2016

IJRCI

View full text Add to dashboard Cite

“…Classification criteria for rheumatoid arthritis as per the 2010 ACR/EULAR [3] were considered while including the patient for study. The study was approved by the Institutional Ethics Committee.…”

Section: Methodsmentioning

confidence: 99%

“…The course of RA ranges from mild arthritis to progressive joint destruction [2,3]. Genetic factors like presence of HLA -DRB1*04 alleles combined with smoking have shown to increase the risk of developing RA [2].…”

mentioning

confidence: 99%

“…Anti Cyclic Citrullinated Antibodies and antibodies to Citrullinated Vimentin have now been described as specific antigens of RA and antibodies to citrullinated proteins/peptides (ACPAs) are included in 2010 ACR/EULAR Rheumatoid Arthritis (RA) Classification Criteria [3,8]. ACPAs are a family of autoantibodies seen in RA patients and include antiperinuclear factor (APF), antikeratin antibodies (AKA), antifilaggrin antibodies, and anticyclic citrullinated peptide (anti-CCP) antibodies.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Anti- Cyclic Citrullinated Peptide Antibodies: Clinical utility and their role as early prognostic markers in Erosive Rheumatoid Arthritis.

Aniyappanavar¹,

Shruthi²,

Rajendran³

2015

Int Jour of Biomed Res

View full text Add to dashboard Cite

Objectives: To assess the diagnostic utility of anti-cyclic citrullinated protein antibody (anti-CCP) in comparison to rheumatoid factor (RF) in diagnosis of rheumatoid arthritis (RA) and to determine its prognostic value in erosive rheumatoid arthritis. Materials and Methods:The study included 60 patients with clinically suspected RA. Anti-CCP was measured by enzyme-linked immunosorbent assay (ELISA) and rheumatoid factor (RF) by nephalometry. The seropositivity with RF and ACCP antibodies were studied in comparison with radiographic changes and joint symptoms which included presence and duration of joint involvement-multiple joints, small joints, symmetric joints, stiffness or swelling of joints. Results: Among the 60 patients, the mean age for RA was found to be 43 years. A higher seropositivity was found among the females. The sensitivity and specificity of anti-CCP reactivity for the diagnosis of RA were 38.3 and 100 respectively. Among the symptoms studied, small joint involvement and involvement of multiple joints showed a positive association with serologically positive individuals. Patients with high anti-CCP antibody titres showed higher RF titres and severe radiographic erosions. Conclusion: Anti CCP antibodies are highly specific for rheumatoid arthritis. A combined diagnosis using both high titers of anti-CCP antibodies and a positive RF test markedly improves RA diagnostic specificity. ACCP antibody detection helps in early diagnosis as well as detection of progressive joint damage.

show abstract

“…19 ). 15 years later anti-keratin antibodies (AKA) were reported, which were RA specific and reacted with keratinized tissues of the oesophagus and interestingly also with cells from human hair follicles.…”

Section: Patients' Perspectives and Involvementmentioning

confidence: 99%

Managing rheumatic and musculoskeletal diseases — past, present and future

et al. 2017

View full text Add to dashboard Cite

Progress in rheumatology has been remarkable in the last 70 years impacting favourably on quality of life for people with rheumatic and musculoskeletal diseases. Therapeutics have advanced from early developments including the introduction of glucocorticoids, the general use of methotrexate and other disease modifying agents, through to the advent of biologic and recently small molecule JAK-inhibitors. Strategic approaches using such agents also transformed outcomes. Similarly, non-pharmacologic management of RMDs including surgery, physical and occupational therapy have contributed greatly to progress delivered within the multi-disciplinary team. Breakthroughs in pathogenesis understanding, diagnostics, and the use of 'big data' continue to drive the field. Critically, and especially going forward, the patient is at the centre of management strategies and the future research agenda.

show abstract

Role of anti-citrullinated protein antibodies in diagnosis and prognosis of rheumatoid arthritis

Cited by 47 publications

References 49 publications

Chronic tophaceous gout with anti-CCP positivity: A rare presentation

Chronic tophaceous gout with anti-CCP positivity: A rare presentation

Anti- Cyclic Citrullinated Peptide Antibodies: Clinical utility and their role as early prognostic markers in Erosive Rheumatoid Arthritis.

Managing rheumatic and musculoskeletal diseases — past, present and future

Contact Info

Product

Resources

About